JP2009511599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511599A5 JP2009511599A5 JP2008535728A JP2008535728A JP2009511599A5 JP 2009511599 A5 JP2009511599 A5 JP 2009511599A5 JP 2008535728 A JP2008535728 A JP 2008535728A JP 2008535728 A JP2008535728 A JP 2008535728A JP 2009511599 A5 JP2009511599 A5 JP 2009511599A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- composition
- aliphatic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000001931 aliphatic group Chemical group 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000001118 alkylidene group Chemical group 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 7
- -1 1,2-methylenedioxy Chemical group 0.000 claims 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 208000000003 Breakthrough pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72568605P | 2005-10-12 | 2005-10-12 | |
| PCT/US2006/040156 WO2007047474A2 (en) | 2005-10-12 | 2006-10-12 | Biphenyl derivatives as modulators of voltage gated ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511599A JP2009511599A (ja) | 2009-03-19 |
| JP2009511599A5 true JP2009511599A5 (enExample) | 2009-11-05 |
Family
ID=37836784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535728A Pending JP2009511599A (ja) | 2005-10-12 | 2006-10-12 | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7683083B2 (enExample) |
| EP (1) | EP1934191B1 (enExample) |
| JP (1) | JP2009511599A (enExample) |
| KR (1) | KR20080059292A (enExample) |
| CN (1) | CN101365690A (enExample) |
| AT (1) | ATE551333T1 (enExample) |
| AU (1) | AU2006304283B2 (enExample) |
| CA (1) | CA2624831A1 (enExample) |
| ES (1) | ES2383090T3 (enExample) |
| IL (1) | IL190632A0 (enExample) |
| NO (1) | NO20082165L (enExample) |
| NZ (1) | NZ567570A (enExample) |
| RU (1) | RU2008118350A (enExample) |
| WO (1) | WO2007047474A2 (enExample) |
| ZA (1) | ZA200803704B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| CN101218235A (zh) | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| ZA200802977B (en) * | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| US7683083B2 (en) * | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| AU2008321142A1 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| EP2307412A2 (en) * | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| EP2935257B1 (en) * | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| US20200270237A1 (en) * | 2017-10-19 | 2020-08-27 | Esteve Pharmaceuticals, S.A. | New alkoxyamino compounds for treating pain and pain related conditions |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| SG11202100130QA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
| WO2020163236A1 (en) * | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Treating long qt syndrome |
| MX2023014819A (es) | 2021-06-14 | 2024-03-21 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| AU2002353716A1 (en) * | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| EP1461327A1 (en) * | 2001-11-22 | 2004-09-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| US7683083B2 (en) * | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
-
2006
- 2006-10-12 US US11/546,669 patent/US7683083B2/en active Active
- 2006-10-12 CN CNA2006800448581A patent/CN101365690A/zh active Pending
- 2006-10-12 AU AU2006304283A patent/AU2006304283B2/en not_active Ceased
- 2006-10-12 KR KR1020087011101A patent/KR20080059292A/ko not_active Withdrawn
- 2006-10-12 AT AT06816908T patent/ATE551333T1/de active
- 2006-10-12 ES ES06816908T patent/ES2383090T3/es active Active
- 2006-10-12 NZ NZ567570A patent/NZ567570A/en not_active IP Right Cessation
- 2006-10-12 JP JP2008535728A patent/JP2009511599A/ja active Pending
- 2006-10-12 RU RU2008118350/04A patent/RU2008118350A/ru not_active Application Discontinuation
- 2006-10-12 CA CA002624831A patent/CA2624831A1/en not_active Abandoned
- 2006-10-12 EP EP06816908A patent/EP1934191B1/en not_active Not-in-force
- 2006-10-12 WO PCT/US2006/040156 patent/WO2007047474A2/en not_active Ceased
-
2008
- 2008-04-06 IL IL190632A patent/IL190632A0/en unknown
- 2008-04-29 ZA ZA2008/03704A patent/ZA200803704B/en unknown
- 2008-05-13 NO NO20082165A patent/NO20082165L/no not_active Application Discontinuation
-
2010
- 2010-02-01 US US12/697,671 patent/US8236833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543785A5 (enExample) | ||
| JP2009524591A5 (enExample) | ||
| JP2008540661A5 (enExample) | ||
| JP2009507851A5 (enExample) | ||
| CA2651375C (en) | Treatment of cell proliferative disorders | |
| ES2378776T3 (es) | Derivado de ácido aminocarboxílico y uso medicinal del mismo | |
| JP2022119990A (ja) | アポトーシス誘発剤 | |
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| WO2018208727A1 (en) | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof | |
| JP2019523228A (ja) | カンナビノイドプロドラッグの製造のための方法、薬学的製剤、およびその使用 | |
| EA038141B1 (ru) | Способы лечения вирусных инфекций arenaviridae и coronaviridae | |
| RU2008118350A (ru) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов | |
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| IL187553A (en) | Use of L-dioxythimidine history in combination with at least one other anti-cancer agent for the preparation of a drug for the treatment of cancer | |
| TW200302227A (en) | Geranyl group-containing compounds | |
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| JP6333996B2 (ja) | がんを予防または治療するための、ブロモドメイン阻害化合物およびそれを含む医薬組成物 | |
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| JP7399171B2 (ja) | 腎疾患に対するシュウ酸カルシウム結晶化阻害剤 | |
| EP2139463B1 (en) | Anti-infective agents | |
| JP2008540666A5 (enExample) | ||
| ES2945062T3 (es) | Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| AU593271B2 (en) | Antiviral treatments | |
| JP2025138791A (ja) | 慢性腎臓病の治療又は予防方法 |